Perspective Therapeutics Inc (CATX) Stock Price, Quote & News

Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a bet...

Industry: Medical Devices

Sector: Healthcare

Phone: 206 676 0900

Website: www.perspectivetherapeutics.com

Address:

2401 Elliott Avenue, Suite 320, Seattle, United States

jto2 Aug. 23 at 9:59 AM

$CATX now has direct ties to “government” through its participation in the FNIH Cancer Project, along with the recent visit from ruling party senators, House members, and cabinet officials. The timing is very interesting, especially as major institutions are actively accumulating $CATX

0 · Reply

JohnsonGaps Aug. 23 at 8:30 AM

$CATX Perspective Therapeutics Inc is a clinical stage radiopharma company with high development risk

0 · Reply

noble23 Aug. 23 at 4:30 AM

$CATX there really trying to scare out the small fish, 18$ here we come!

0 · Reply

jto2 Aug. 23 at 12:35 AM

$CATX After-hours prints near $3.44 look like arranged trades, not real selling. Shorts struggling to move it in regular hours = bullish setup. Upside bias into next week.

0 · Reply

carepolice Aug. 22 at 11:54 PM

$CATX what are the upcoming catalysts here? anything to expect in near future or more likely end on 2026 whe they gonna raise money again?

0 · Reply

jto2 Aug. 22 at 6:25 PM

UBS believes the Lead-based $CATX ’s pipeline could demonstrate "SUPERIOR efficacy and safety" compared to "current Standard-of-Care" beta-emitting radiopharmaceuticals. UBS $18 price target on $CATX ahead of ESMO data in October.

0 · Reply

markbass2341 Aug. 22 at 5:42 PM

$CATX

1 · Reply

ggtfdf Aug. 22 at 3:23 PM

$CATX https://www.investing.com/news/analyst-ratings/perspective-therapeutics-stock-holds-buy-rating-at-ubs-ahead-of-esmo-data-93CH-4206838 UBS maintained its Buy rating and $18.00 price target on Perspective Therapeutics Inc (NYSE:CATX)

2 · Reply

Kingtan Aug. 22 at 2:43 PM

$CATX 😎

0 · Reply

JDinvestments Aug. 22 at 11:33 AM

$CATX STRONG BUYOUT 🔥🔥🔥💰💰💰🚀🚀🚀🚀🚀🚀👋👋👋🤡🤡🤡

0 · Reply

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 2, 2025, 8:53 AM EDT - 22 days ago

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Jul 24, 2025, 12:45 PM EDT - 4 weeks ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 15, 2025, 7:00 AM EDT - 5 weeks ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jun 21, 2025, 8:00 AM EDT - 2 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 2 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

May 30, 2025, 5:21 PM EDT - 3 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 12, 2025, 4:36 PM EDT - 3 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 1, 2025, 7:00 AM EDT - 4 months ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Apr 23, 2025, 12:25 PM EDT - 4 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 17, 2025, 7:00 AM EDT - 4 months ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 11, 2025, 7:00 AM EDT - 4 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 31, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 26, 2025, 4:10 PM EDT - 5 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 17, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 13, 2025, 2:52 PM EDT - 5 months ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Feb 26, 2025, 7:00 AM EST - 6 months ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 21, 2025, 7:00 AM EST - 6 months ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 5, 2025, 7:00 AM EST - 7 months ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Jan 24, 2025, 7:00 AM EST - 7 months ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 6, 2025, 8:00 AM EST - 8 months ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Dec 23, 2024, 11:13 AM EST - 8 months ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 20, 2024, 4:16 PM EST - 8 months ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Nov 27, 2024, 7:00 AM EST - 9 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 21, 2024, 7:15 AM EST - 9 months ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 15, 2024, 4:08 PM EST - 10 months ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 12, 2024, 4:05 PM EST - 10 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Oct 29, 2024, 7:00 AM EDT - 10 months ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 23, 2024, 7:00 AM EDT - 10 months ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 16, 2024, 7:00 AM EDT - 11 months ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 11, 2024, 12:05 PM EDT - 11 months ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 8:30 AM EDT - 11 months ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 10, 2024, 5:14 PM EDT - 11 months ago

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Oct 7, 2024, 7:00 AM EDT - 11 months ago

Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Oct 2, 2024, 3:11 PM EDT - 11 months ago

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Oct 2, 2024, 12:10 PM EDT - 11 months ago

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Sep 30, 2024, 7:00 AM EDT - 11 months ago

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces Inclusion in the Russell 3000® Index

Jun 11, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces 1-for-10 Reverse Stock Split

Jun 10, 2024, 4:10 PM EDT - 1 year ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

May 24, 2024, 8:01 AM EDT - 1 year ago

Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

May 20, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024

May 15, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

May 3, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate at Upcoming May Investor Conferences

May 2, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results

jto2 Aug. 23 at 9:59 AM

0 · Reply

JohnsonGaps Aug. 23 at 8:30 AM

$CATX Perspective Therapeutics Inc is a clinical stage radiopharma company with high development risk

0 · Reply

noble23 Aug. 23 at 4:30 AM

$CATX there really trying to scare out the small fish, 18$ here we come!

0 · Reply

jto2 Aug. 23 at 12:35 AM

$CATX After-hours prints near $3.44 look like arranged trades, not real selling. Shorts struggling to move it in regular hours = bullish setup. Upside bias into next week.

0 · Reply

carepolice Aug. 22 at 11:54 PM

$CATX what are the upcoming catalysts here? anything to expect in near future or more likely end on 2026 whe they gonna raise money again?

0 · Reply

jto2 Aug. 22 at 6:25 PM

0 · Reply

markbass2341 Aug. 22 at 5:42 PM

$CATX

1 · Reply

ggtfdf Aug. 22 at 3:23 PM

2 · Reply

Kingtan Aug. 22 at 2:43 PM

$CATX 😎

0 · Reply

JDinvestments Aug. 22 at 11:33 AM

$CATX STRONG BUYOUT 🔥🔥🔥💰💰💰🚀🚀🚀🚀🚀🚀👋👋👋🤡🤡🤡

0 · Reply

Xanderzzzzzzz Aug. 22 at 10:15 AM

$CATX Oppenheimer

0 · Reply

Xanderzzzzzzz Aug. 22 at 10:14 AM

$CATX

0 · Reply

ReversalJunkie Aug. 22 at 4:46 AM

$CATX Perspective Therapeutics is a clinical stage radiopharma company with highly speculative prospects dependent on regulatory success

2 · Reply

jto2 Aug. 22 at 3:50 AM

The Supreme Court/Trump admin ruling is about slashing DEI-targeted research funding, not NIH’s core biomedical research funding. $CATX don’t rely on DEI-targeted funding and catx is largely insulated, enough cash to run.

0 · Reply

markbass2341 Aug. 22 at 3:24 AM

$CATX https://www.mlive.com/news/2025/08/supreme-court-allows-trump-admin-to-slash-research-funding-in-push-to-cut-dei-efforts.html

0 · Reply

jto2 Aug. 22 at 3:21 AM

$CATX So that’s Senate + House + Cabinet officials all at one site. It’s a rare and strong signal of federal support. Senator Ernst even posted about his visit to Perspective Therapeutics. https://www.ernst.senate.gov/news/press-releases/ernst-miller-meeks-loeffler-tout-importance-of-driving-innovation-in-the-heartland

0 · Reply

Xanderzzzzzzz Aug. 21 at 9:23 PM

$CATX

0 · Reply

Xanderzzzzzzz Aug. 21 at 8:24 PM

$CATX support from SBA

1 · Reply

Xanderzzzzzzz Aug. 21 at 8:24 PM

$CATX

0 · Reply

jto2 Aug. 21 at 6:51 PM

$CATX Wow, how long can the shorts keep shuffling like this? The algo probably won’t change unless new buys come in. Longs are holding tight, but there’s no fresh buying. Let’s see how it closes today.

0 · Reply

outlawinvestor1 Aug. 21 at 3:32 PM

$RADX nice table of historical comps in radiopharm. we’re super early here! $NVS $BMY $LNTH $CATX

1 · Reply

mds04086 Aug. 21 at 3:02 PM

$CATX if only we'd hit that huge gap up from 4.54-6.01, so close

0 · Reply

Market Cap	273.29M
Revenue (ttm)	1.45M
Net Income (ttm)	-79.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,467.59%
Debt to Equity Ratio	0.01

Volume	581,800
Avg Vol	993,812
Day's Range	N/A - N/A
Shares Out	74.26M
Stochastic %K	50%
Beta	1.17
Analysts	Strong Sell
Price Target	$12.92